182 related articles for article (PubMed ID: 32985286)
1. Using forced vital capacity (FVC) in the clinic to monitor patients with idiopathic pulmonary fibrosis (IPF): pros and cons.
Nathan SD; Wanger J; Zibrak JD; Wencel ML; Burg C; Stauffer JL
Expert Rev Respir Med; 2021 Feb; 15(2):175-181. PubMed ID: 32985286
[TBL] [Abstract][Full Text] [Related]
2. Variability of forced vital capacity in progressive interstitial lung disease: a prospective observational study.
Veit T; Barnikel M; Crispin A; Kneidinger N; Ceelen F; Arnold P; Munker D; Schmitzer M; Barton J; Schiopu S; Schiller HB; Frankenberger M; Milger K; Behr J; Neurohr C; Leuschner G
Respir Res; 2020 Oct; 21(1):270. PubMed ID: 33076914
[TBL] [Abstract][Full Text] [Related]
3. Disease Behaviour During the Peri-Diagnostic Period in Patients with Suspected Interstitial Lung Disease: The STARLINER Study.
Wijsenbeek MS; Bendstrup E; Valenzuela C; Henry MT; Moor CC; Jouneau S; Fois AG; Moran-Mendoza O; Anees S; Mirt M; Bengus M; Gilberg F; Kirchgaessler KU; Vancheri C
Adv Ther; 2021 Jul; 38(7):4040-4056. PubMed ID: 34117601
[TBL] [Abstract][Full Text] [Related]
4. Daily Home Spirometry: An Effective Tool for Detecting Progression in Idiopathic Pulmonary Fibrosis.
Russell AM; Adamali H; Molyneaux PL; Lukey PT; Marshall RP; Renzoni EA; Wells AU; Maher TM
Am J Respir Crit Care Med; 2016 Oct; 194(8):989-997. PubMed ID: 27089018
[TBL] [Abstract][Full Text] [Related]
5. Home spirometry in patients with idiopathic pulmonary fibrosis: data from the INMARK trial.
Noth I; Cottin V; Chaudhuri N; Corte TJ; Johannson KA; Wijsenbeek M; Jouneau S; Michael A; Quaresma M; Rohr KB; Russell AM; Stowasser S; Maher TM;
Eur Respir J; 2021 Jul; 58(1):. PubMed ID: 33419890
[TBL] [Abstract][Full Text] [Related]
6. Change in forced vital capacity and associated subsequent outcomes in patients with newly diagnosed idiopathic pulmonary fibrosis.
Reichmann WM; Yu YF; Macaulay D; Wu EQ; Nathan SD
BMC Pulm Med; 2015 Dec; 15():167. PubMed ID: 26714746
[TBL] [Abstract][Full Text] [Related]
7. [Position Paper: Significance of the Forced Vital Capacity in Idiopathic Pulmonary Fibrosis].
Behr J; Bonella F; Bonnet R; Gläser S; Grohé C; Günther A; Koschel D; Kreuter M; Kirsten D; Krögel C; Markart P; Müller-Quernheim J; Neurohr C; Pfeifer M; Prasse A; Schönfeld N; Schreiber J; Wirtz H; Witt C; Costabel U
Pneumologie; 2015 Aug; 69(8):455-8. PubMed ID: 26227628
[TBL] [Abstract][Full Text] [Related]
8. The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis.
Assayag D; Vittinghoff E; Ryerson CJ; Cocconcelli E; Tonelli R; Hu X; Elicker BM; Golden JA; Jones KD; King TE; Koth LL; Lee JS; Ley B; Shum AK; Wolters PJ; Ryu JH; Collard HR
Respir Med; 2015 Aug; 109(8):1058-62. PubMed ID: 26140806
[TBL] [Abstract][Full Text] [Related]
9. Clinical management and acute exacerbations in patients with idiopathic pulmonary fibrosis in Spain: results from the OASIS study.
Cano-Jiménez E; Romero Ortiz AD; Villar A; Rodríguez-Nieto MJ; Ramon A; Armengol S
Respir Res; 2022 Sep; 23(1):235. PubMed ID: 36071483
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of forced vital capacity decline prior to and following antifibrotic therapy in idiopathic pulmonary fibrosis.
Aono Y; Nakamura Y; Kono M; Nakamura H; Yokomura K; Imokawa S; Toyoshima M; Yasui H; Hozumi H; Karayama M; Suzuki Y; Furuhashi K; Enomoto N; Fujisawa T; Inui N; Suda T
Ther Adv Respir Dis; 2020; 14():1753466620953783. PubMed ID: 32928050
[TBL] [Abstract][Full Text] [Related]
11. EMPIRE Registry, Czech Part: Impact of demographics, pulmonary function and HRCT on survival and clinical course in idiopathic pulmonary fibrosis.
Doubková M; Švancara J; Svoboda M; Šterclová M; Bartoš V; Plačková M; Lacina L; Žurková M; Binková I; Bittenglová R; Lošťáková V; Merta Z; Šišková L; Tyl R; Lisá P; Šuldová H; Petřík F; Pšikalová J; Řihák V; Snížek T; Reiterer P; Homolka J; Musilová P; Lněnička J; Palúch P; Hrdina R; Králová R; Hortvíková H; Strenková J; Vašáková M
Clin Respir J; 2018 Apr; 12(4):1526-1535. PubMed ID: 28862397
[TBL] [Abstract][Full Text] [Related]
12. Deterioration of high-resolution computed tomography findings predicts disease progression after initial decline in forced vital capacity in idiopathic pulmonary fibrosis patients treated with pirfenidone.
Higo H; Miyahara N; Taniguchi A; Senoo S; Itano J; Watanabe H; Oda N; Kayatani H; Ichikawa H; Shibayama T; Kajimoto K; Tanimoto Y; Kanehiro A; Maeda Y; Kiura K;
Respir Investig; 2020 May; 58(3):185-189. PubMed ID: 32102769
[TBL] [Abstract][Full Text] [Related]
13. Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients.
Feng H; Zhao Y; Li Z; Kang J
Ther Adv Respir Dis; 2020; 14():1753466620963015. PubMed ID: 33070705
[TBL] [Abstract][Full Text] [Related]
14. Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis.
Zappala CJ; Latsi PI; Nicholson AG; Colby TV; Cramer D; Renzoni EA; Hansell DM; du Bois RM; Wells AU
Eur Respir J; 2010 Apr; 35(4):830-6. PubMed ID: 19840957
[TBL] [Abstract][Full Text] [Related]
15. A review of the challenges, learnings and future directions of home handheld spirometry in interstitial lung disease.
Maher TM; Schiffman C; Kreuter M; Moor CC; Nathan SD; Axmann J; Belloni P; Bengus M; Gilberg F; Kirchgaessler KU; Wijsenbeek MS
Respir Res; 2022 Nov; 23(1):307. PubMed ID: 36369156
[TBL] [Abstract][Full Text] [Related]
16. Effect of continued antifibrotic therapy after forced vital capacity decline in patients with idiopathic pulmonary fibrosis; a real world multicenter cohort study.
Adams CJ; Shapera S; Ryerson CJ; Assayag D; Johannson KA; Fell CD; Morisset J; Manganas H; Kolb M; Hambly N; Cox G; Khalil N; Marcoux V; Wilcox PG; To T; Sadatsafavi M; Halayko AJ; Gershon A; Garlick K; Fisher JH
Respir Med; 2022 Jan; 191():106722. PubMed ID: 34959146
[TBL] [Abstract][Full Text] [Related]
17. Home Monitoring in Patients with Idiopathic Pulmonary Fibrosis. A Randomized Controlled Trial.
Moor CC; Mostard RLM; Grutters JC; Bresser P; Aerts JGJV; Chavannes NH; Wijsenbeek MS
Am J Respir Crit Care Med; 2020 Aug; 202(3):393-401. PubMed ID: 32325005
[No Abstract] [Full Text] [Related]
18. Home monitoring improves endpoint efficiency in idiopathic pulmonary fibrosis.
Johannson KA; Vittinghoff E; Morisset J; Lee JS; Balmes JR; Collard HR
Eur Respir J; 2017 Jul; 50(1):. PubMed ID: 28679608
[TBL] [Abstract][Full Text] [Related]
19. Serial 6-month change in forced vital capacity predicts subsequent decline and mortality in Japanese patients with newly diagnosed idiopathic pulmonary fibrosis.
Toi Y; Takei R; Kimura T; Kataoka K; Matsuda T; Yokoyama T; Fukuoka J; Johkoh T; Kondoh Y
Respir Investig; 2021 May; 59(3):335-341. PubMed ID: 33551330
[TBL] [Abstract][Full Text] [Related]
20. Serial decline in lung volume parameters on computed tomography (CT) predicts outcome in idiopathic pulmonary fibrosis (IPF).
Robbie H; Wells AU; Fang C; Jacob J; Walsh SLF; Nair A; Camoras R; Desai SR; Devaraj A
Eur Radiol; 2022 Apr; 32(4):2650-2660. PubMed ID: 34716781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
